These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15145878)

  • 1. Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.
    Montalescot G; Andersen HR; Antoniucci D; Betriu A; de Boer MJ; Grip L; Neumann FJ; Rothman MT
    Heart; 2004 Jun; 90(6):676-7. PubMed ID: 15145878
    [No Abstract]   [Full Text] [Related]  

  • 2. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What is best for patients with STEMI on the way to primary percutaneous coronary intervention?].
    Opolski G
    Kardiol Pol; 2012; 70(3):222. PubMed ID: 22430398
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of ST-segment elevation myocardial infarction in EDs.
    Diercks DB; Kontos MC; Weber JE; Amsterdam EA
    Am J Emerg Med; 2008 Jan; 26(1):91-100. PubMed ID: 18082788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials.
    Brodie BR; Gersh BJ; Stuckey T; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Grines CL; Cox D; Parise H; Prasad A; Lansky AJ; Mehran R; Stone GW
    J Am Coll Cardiol; 2010 Jul; 56(5):407-13. PubMed ID: 20650362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry).
    Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Janzon M; Mielecki W; Zmudka K; Dubiel JS; Dudek D
    Kardiol Pol; 2012; 70(3):215-21. PubMed ID: 22430397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion.
    Krucoff MW; Johanson P; Baeza R; Crater SW; Dellborg M
    Circulation; 2004 Dec; 110(25):e533-9. PubMed ID: 15611375
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.
    Montalescot G; Andersen HR; Antoniucci D; Betriu A; de Boer MJ; Grip L; Neumann FJ; Rothman MT
    Heart; 2004 Jun; 90(6):e37. PubMed ID: 15145901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.
    De Luca G; Suryapranata H; Grimaldi R; Chiariello M
    QJM; 2005 Sep; 98(9):633-41. PubMed ID: 16040669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
    Zeymer U; Tebbe U; Weber M; Vohringer HF; Jaksch R; Bischoff KO; Toepel W; Marsalek P; Horn S; Neuhaus KL;
    J Invasive Cardiol; 2003 Jul; 15(7):385-9. PubMed ID: 12840235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.
    Gersh BJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1292-4. PubMed ID: 21232724
    [No Abstract]   [Full Text] [Related]  

  • 12. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
    Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
    Cox DA; Stone GW; Grines CL; Stuckey T; Zimetbaum PJ; Tcheng JE; Turco M; Garcia E; Guagliumi G; Iwaoka RS; Mehran R; O'Neill WW; Lansky AJ; Griffin JJ;
    Am J Cardiol; 2006 Aug; 98(3):331-7. PubMed ID: 16860018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal reperfusion strategy for acute myocardial infarction.
    Dzielicka E; Swanton H
    Br J Hosp Med (Lond); 2008 Jan; 69(1):18-23. PubMed ID: 18293723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter by Niccoli et al regarding article, "intracoronary versus intravenous administration of abciximab in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of st-segment elevation myocardial infarction (CICERO) trial".
    Niccoli G; Cosentino N; Crea F
    Circulation; 2011 Aug; 124(8):e230; author reply e231. PubMed ID: 21859979
    [No Abstract]   [Full Text] [Related]  

  • 16. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA; Lincoff AM
    Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute ST-segment elevation myocardial infarction. I. Reperfusion therapy.
    Glancy DL; Breaux DM; Subramaniam PN; Pappas ND
    J La State Med Soc; 2002; 154(4):183-90; quiz 190. PubMed ID: 12236401
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
    Marzocchi A; Manari A; Piovaccari G; Marrozzini C; Marra S; Magnavacchi P; Sangiorgio P; Marinucci L; Taglieri N; Gordini G; Binetti N; Guiducci V; Franco N; Reggiani ML; Saia F;
    Eur Heart J; 2008 Dec; 29(24):2972-80. PubMed ID: 18940887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 20. Abciximab in ST-elevation acute myocardial infarction occurring in a heart transplant recipient and treated with stenting.
    Varotto L; La Vecchia L; Fontanelli A
    J Invasive Cardiol; 2006 Apr; 18(4):E134-6. PubMed ID: 16723747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.